Present and Future Post-marketing Drug Safety Assessment in Japan: A PMDA Perspective
Authors:
Open Access
- 24 April 2026
- journal article
- Published by Springer Nature in Therapeutic Innovation & Regulatory Science
- Vol. 60 (4) , 938-940
Abstract
For pharmacovigilance, the Pharmaceuticals and Medical Devices Agency in Japan has utilized real world data (RWD) from multiple sources, including individual case safety reports, and medical information databases that capture routinely collected data from clinical practice. These RWD have their own characteristics with advantages and disadvantages. In this commentary, we describe current and future direction of post-marketing drug safety assessment in Japan.Keywords
This publication has 11 references indexed in Scilit:
- Core Concepts in Pharmacoepidemiology: Multi‐Database Distributed Data NetworksPharmacoepidemiology and Drug Safety, 2025
- New Function for Safety Signal Monitoring in MID‐NET®: The Case of an Anti‐COVID‐19 DrugClinical and Translational Science, 2025
- PMDA Perspective on RWD/RWE Utilization for Regulatory Purposes Including Assessment on the Impacts of Regulatory Actions and Safety Risk of a Drug at Postmarketing StagePharmacoepidemiology and Drug Safety, 2024
- Updated Information on NDBAnnals of Clinical Epidemiology, 2024
- Use of National Database of Health Insurance Claims and Specific Health Checkups for examining practical utilization and safety signal of a drug to support regulatory assessment on postmarketing drug safety in JapanFrontiers in Medicine, 2023
- Data-Driven Identification of Adverse Event Reporting Patterns for Japan in VigiBase, the WHO Global Database of Individual Case Safety ReportsDrug Safety, 2019
- Establishment of the MID‐NET® medical information database network as a reliable and valuable database for drug safety assessments in JapanPharmacoepidemiology and Drug Safety, 2019
- The MIHARI project: establishing a new framework for pharmacoepidemiological drug safety assessments by the Pharmaceuticals and Medical Devices Agency of JapanPharmacoepidemiology and Drug Safety, 2016
- The FDA's sentinel initiative—A comprehensive approach to medical product surveillanceClinical Pharmacology & Therapeutics, 2015
- Principles of Signal Detection in PharmacovigilanceDrug Safety, 1997